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doi:10.1016/j.jfma.2011.09.004Background/Purpose: To compare the efficacy and safety of topical cromolyn between with
and without preservative for the treatment of allergic conjunctivitis.
Methods: A double-masked study was performed in patients with allergic conjunctivitis. Each
cromolyn sodium 2% ophthalmic solution with or without 0.01% benzalkonium chloride (BAK)
was randomized to apply on either eye. The efficacy and safety were evaluated every other
week by a questionnaire about ocular itching, redness and foreign body sensation, and objec-
tive scores of conjunctival redness, chemosis, cornea erosion and discharge using slit-lamp bio-
microscopy. An overall response was also rated by physician’s impression.
Results: A total of 37 subjects were enrolled in this study but only 33 completed the study. All
of subjective questionnaire scores showed a significant improvement after treatment in both
groups. Objective score of redness significantly decreased after treatment in either groups but
not chemisos or discharge. After 4-week treatment, corneal erosion diminished significantly in
the group without preservative but not in the group with 0.01% BAK. There was no significant
difference between with and without 0.01% BAK groups in each subjective or objective score.
No adverse effect related with medication was observed.
Conclusion: Cromolyn 2 % ophthalmic solution was effective and safe to treat allergic conjunc-
tivitis. A short-term use of cromolyn 2 % ophthalmic solution with 0.01% BAK would not cause
any significant toxicity in patients with allergic conjunctivitis. Preservative-free cromolyn may
be beneficial to the compromised eyes or eyes required of long-term medication.
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Comparison of cromolyn for allergic conjunctivitis treatment 691Allergic conjunctivitis is the most common form of ocular
1
Topical corticosteroids, nonsteroidal anti-inflammatory
allergic disease, affecting 5%e20% of the population. Other
types of ocular allergies include vernal and atopic kerato-
conjunctivitis. Although these occur less frequently, they are
more severe than seasonal or perennial allergic conjuncti-
vitis. Perennial allergic conjunctivitis is characterized by the
presence of itching, redness, swelling, tearing, and mucous
discharge throughout the year. Allergic conjunctivitis is
induced by immunoglobulin E (IgE)-mediated, type 1 hyper-
sensitivity reactions that involve histamine from degranu-
lated mast cells.2 Mast cell degranulation also releases
a cascade of allergic and inflammatory mediators.3 Hista-
mine has been shown to induce itching in the ocular surface
through H1 receptors and redness through both H1 and H2
receptors.4 Itching is one of the major symptoms of allergic
conjunctivitis, and it has a dramatic effect on a patient’s
quality of life. In addition, perennial allergic conjunctivitis is
often accompanied by the nasal symptoms of rhinitis. The
most common cause of allergic conjunctivitis is the house-
hold dust mite (Dermatophagoides pteronyssinus).2
The treatment options for patients with allergic conjunc-
tivitis include antihistamines, topical mast cell stabilizers,
topical antihistamine-mast cell stabilizers, nonsteroidal anti-
inflammatory drugs, and corticosteroids.5 Cromolyn sodium,
a mast cell stabilizer, is a good substitute for topical steroids
for mild to moderate allergic eye diseases because of its
steroid-sparing effect and good efficacy.6 Cromolyn is poorly
absorbed systemically when used topically and therefore has
an excellent safety record.7 Cromolyn sodium acts by inhib-
iting both the degranulation of sensitized mast cells and the
release of histamine from the conjunctival mast cells. Cro-
molyn sodium 2% ophthalmic solution has been used for the
treatment of allergic ocular disease.8 Most of these
ophthalmic solutions contain preservatives to prevent
contamination. It is well known that preservatives can cause
ocular irritation and tissue damage.9e12 Therefore, a formu-
lation containing the active ingredient without any preser-
vative has been developed. The key alternative method to
accomplish this goal is to pack the ophthalmic solution in an
aseptic bottle. Allergo-COMOD [Ursapharm Arzneimittel
GmbH & Co. KG, Germany] is a sterile preservative-free
ophthalmic solution containing cromolyn sodium. The objec-
tive of this study is to compare the efficacy and safety of
cromolyn sodium without preservative (Allergo-COMOD) to
that with preservative (Allergocrom [Ursapharm Arzneimittel
GmbH & Co. KG, Germany]) in patients with allergic
conjunctivitis after treatment for 4 weeks.Patients and methods
Patients were recruited from the outpatient clinic at the
Department of Ophthalmology, National Taiwan University.
The patients (18e70 years of age) had seasonal or perennial
allergic conjunctivitis, which was diagnosed on the basis of
their allergy history, and at least one of the following
bilateral symptoms and signs: itching, tearing, eyelid
swelling, conjunctival hyperemia, chemosis, or conjunc-
tival papillary reaction. Patients were excluded from the
study if they had any history of ocular surgery, asthma,
diabetic retinopathy, or rheumatoid arthritis, or if they
were pregnant, lactating, or hypersensitive to cromolyn.drugs, antihistamines, other mast cell stabilizers, immu-
nosuppressants, and vasoconstrictors were prohibited
during the study period. If these topical medications had
been used before, a washout period of 7 days was required.
The trial was conducted in accordance with the Declaration
of Helsinki, and it was approved by the Institutional Review
Board of the Research Ethics Committee at National Taiwan
University Hospital in Taiwan. The study was explained well
to all participants and written informed consent was
obtained.
This was a randomized, double-masked, and parallel
study to compare the efficacy and safety of cromolyn
sodium 2% ophthalmic solution with preservative to that
without preservative for the treatment of patients with
allergic conjunctivitis. The study period for each patient
was 5 weeks, including a screening/washout period of
1 week (at Visit 1) and a treatment period of 4 weeks. Each
patient was required to make four visits. At Visit 2, eligible
patients were randomized to receive Allergo-COMOD
(without preservative) in one eye and Allergocrom with
0.01% benzalkonium chloride (BAK) preservative in the
fellow eye four times daily in a double-masked fashion for
4 weeks. The study was double-masked to ensure that the
investigators’ expectations would not influence the assess-
ment of the clinical response. The randomization table and
codes were provided by individuals who packed and labeled
the study medication. The randomization codes placed in
envelopes were generated according to the randomization
table and were distributed to the study site before the
initiation of the study; they were only opened by the
investigator under an emergency situation.
The patients were randomized in balanced blocks with
an equal probability of receiving the study drug in the left
eye (with the control drug in the right eye) or the study
drug in the right eye (with the control drug in the left eye).
Randomization schedules were generated at 1:1 ratio.
Pretreatment and post-treatment subjective evaluations of
the patients were conducted using a questionnaire on
ocular itching, redness, and foreign body sensation, which
were rated on a 10-point scale from 0 Z none to
9 Z severe. The physician used slit-lamp biomicroscopy to
determine the scores of the intensity of conjunctival
redness, chemosis, corneal erosion, and discharge on a 5-
point scale consisting of 1 unit increments: 0Z normal and
4Z complete involvement. The overall response was rated
according to the physician’s impression at each visit
(0 Z clinical cure, 1 Z satisfactory clinical response,
2Z slight clinical improvement, 3 Z clinically unchanged,
4Z slightly clinically worse, and 5Z significantly clinically
worse). The efficacy of the treatment was evaluated by the
net change in the sum of the scores at the last visit
compared to the baseline scores.
The efficacy was analyzed for the intent-to-treat (ITT)
and safety populations. The ITT population included all
randomized patients who received at least one dose of both
study medications and who had at least one postbaseline
assessment for the primary efficacy variable regardless of
their compliance with the protocol. The safety population
included all randomized patients who received at least one
dose of both study medications. The efficacy evaluation
was performed on the ITT population. For patients who
Table 2 Change in the physician’s rating from baseline on
the intensity using slit-lamp images.
Characteristics Allergo-COMOD,
N Z 33
Allergocrom,
N Z 33
p
V2 (baseline, Day 0)
Conjunctival redness
Mean  SD 1.68  0.59 1.65  0.54 0.743
Corneal crosion
Mean  SD 0.50  0.75 0.38  0.60 0.625
Chemosis
Mean  SD 0.06  0.24 0.06  0.24 1.00
Discharge
Mean  SD 0.11  0.32 0.11  0.32 1.00
V3 change from baseline (Week 2)
Conjunctival redness
Mean  SD 0.50  0.51 0.50  0.51 0.676
Corneal erosion
Mean  SD 0.15  0.50 0.06  0.60 0.853
Chemosis
Mean  SD 0.06  0.24 0.06  0.24 1.00
692 Y.-l. Liu et al.used a prohibited agent before the termination of the
study, only the efficacy data obtained before the use of
that agent were included in the efficacy analysis. Safety
endpoints were analyzed using the safety population.
Statistical method
Since the population is so small and the evaluation meth-
odology only from 0e10 or 0e5, the way to test treatment
difference between the group without preservative and the
group with 0.01% BAK changed to the Wilcoxon Rank Sum
test to avoid the normal distribution inadequate. We
adopted the SAS Version 8.1 [SAS institute Inc.], with
procedure NPAR1WAY to test collecting data. Descriptive
statistics, such as mean and standard deviation, were
calculated by the UNIVARIATE procedure. A p value < 0.05
was considered significant.
Results
A total of 37 patients were enrolled in this study after
screening 42 potential candidates. Thirty-three patients
completed the study and 4 dropped out. The reasons for
dropping out included adverse events (two patients), loss of
follow-up (one patient), and protocol violation (one
patient). For the safety evaluation, the adverse events in
these two patients were not related to the test treatment.
No abnormal physical examination or vital signs were
detected throughout the study. A total of 34 patients
(age, 39.2  13.5 years) satisfied the definition of the ITT
population and were included in the ITT analysis. A total of
35 patients satisfied the definition of safety population and
were included in the safety analysis.
The effect of the group without preservative was
compared with the group with 0.01% BAK using the primary
variable. As illustrated in Table 1, the mean baseline scores
were 8.91  5.87 and 9.15  5.83 for the groups without
preservative and with 0.01% BAK, respectively, and no
significant differences existed between the two groups at
baseline (p Z 0.883). At Visit 3, the changes in the mean
patients’ diary scores from baseline were e4.05  5.06 and
e4.71  5.51 for the treatment without preservative and
with BAK groups, respectively, with significant difference
(p < 0.001) in both the groups. This suggested that the
symptoms improved after the treatment in both the groups.
At Visit 4, the changes in the mean score from baselineTable 1 Change in patient scores from baseline.
Characteristics Allergo-COMOD,
N Z 33
Allergocrom,
N Z 33
p
V2 (baseline, Day 0)
Mean  SD 8.91  5.87 9.15  5.83 0.883
V3 change from baseline (Week 2)
Mean  SD 4.05  5.06 4.71  5.51 0.840
V4 change from baseline (Week 4)
Mean  SD 5.04  5.45 5.79  5.82 0.817
SDZ standard deviation; V2Z Visit 2; V3Z Visit 3; V4Z Visit 4.were e5.04  5.45 and e5.79  5.82 for treatment without
preservative and for treatment with preservative groups,
respectively. This indicated that after 4 weeks of treat-
ment, symptoms of patients in both the groups further
improved. The diary scores of each patient, including scores
for ocular itching, redness, and foreign body sensation,
were significantly different before and after treatment
(p < 0.01). However, the mean change in the scores from
the baseline did not differ significantly between the two
groups at Visits 3 and 4, indicating that both the treatments
can relieve the symptoms of allergic conjunctivitis.
Table 2 shows that the mean scores of conjunctival
redness, corneal erosion, chemosis, and discharge rated by
the physician did not differ significantly between the two
groups at baseline Visit 2. At follow-up Visits 3 and 4, the
mean composite sign scores were all decreased and the
redness scores were especially reduced. Statistical analysis
between the scores at baseline Visit 2 and treatment Visits
3 and 4 revealed a significant difference in redness but not
in chemosis or discharge. The score for corneal erosion didDischarge
Mean  SD 0.09  0.38 0.06  0.24 0.332
V4 change from baseline (Week 4)
Conjunctival redness
Mean  SD 1.06  0.95 0.94  1.04 0.343
Corneal erosion
Mean  SD 0.21  0.64 0.15  0.66 0.516
Chemosis
Mean  SD 0.00  0.43 0.00  0.43 1.00
Discharge
Mean  SD 0.06  0.42 0.00  0.35 0.100
SDZ standard deviation; V2Z Visit 2; V3Z Visit 3; V4Z Visit 4.
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ment Visits 3 and 4 in either group, except for a marginal
statistical difference in the corneal erosion at treatment
Visit 4 in the group without preservative (p Z 0.035).
However, no significant difference was observed between
the two groups in all the four scales. Regarding the physi-
cians’ impression scale, the group without preservative was
not significantly superior to the group with 0.01% BAK, but
both the groups exhibited significant improvement (Table 3).
Discussion
In allergic conjunctivitis, mast cells play an important role in
allergen-induced inflammation. Mast-cell degranulation
could cause abrupt release of histamine and tryptase, which
induces ocular itching, vasodilatation, and increased vascular
permeability. Cromolyn sodium is a mast cell stabilizer and
can inhibit the degranulation of sensitized mast cells and
reduce the release of histamine by preventing calcium influx
across the cell membrane. In our study, both groups showed
marked reduction in ocular itching, redness, and foreign body
sensation in patients with allergic conjunctivitis. For the
second efficacy endpoint, which measured the change in the
physicians’ rating from the baseline, conjunctival redness and
corneal erosion improved in both the treatment groups, but
chemosis anddischarge did not improve. Because thebaseline
scores for chemosis and discharge were already low before
treatment, the difference in the scores before and after
treatment would not be significant. In our study, the evalua-
tion from patients and the physician showed that both the
treatments were effective for allergic conjunctivitis and
could reduce conjunctival redness and subjective symptoms.
Both the treatments were safe and well tolerated without
significant difference. The results demonstrated that cro-
molyn 2% ophthalmic solution was effective for treating
allergic conjunctivitis.
Preservatives in topical ophthalmic medications prevent
microbial spoilage of pharmaceutical preparations. They are
essential for sterility because the patients may touch the
opening of the containers with fingers, eyelids, cilia,
conjunctiva, or cornea. However, ophthalmic preservatives
may also damage ocular tissues. Preservatives are potentially
cytotoxic to conjunctival and corneal epithelial cells by
alteration of membrane integrity or cellular metabolism.10
BAK, a commonly used preservative, induces the loss of
mircovilli from the surface cells of cornea at low concentra-
tions, and at higher concentrations, it causes cell
desquamation.11e13 The damages lead to the disruption of theTable 3 Change in the physicians’ impression scores from
baseline.
Characteristics Allergo-COMOD,
N Z 33
Allergocrom,
N Z 33
p
Visit 3 (Week 2)
Mean  SD 1.85  0.42 1.76  0.50 0.423
Visit 4 (Week 4)
Mean  SD 1.21  0.65 1.12  0.65 0.570
SDZ standard deviation; V2Z Visit 2; V3Z Visit 3; V4Z Visit 4.stability of the tear film14,15 and the integrity of the corneal
epithelium16 and also increase ocular surface inflamma-
tion.17,18 Adverse effects, such as burning sensation, foreign
body sensation, and conjunctival hyperemia, will become
more significant, especially in patients with dry eyes and
glaucoma who need frequent, long-term, and sometimes
multiple topical medications containing the preserva-
tives.19,20 Apart from the impact on corneal and conjunctival
epithelial cells, BAK has also been demonstrated to be cyto-
toxic to endothelial cells in in vitro studies.21 When clinicians
prescribe long-term topical solutions, this should be taken
into consideration in high-risk cases, such as those with low
endothelial cell density and extensive epithelial damage.
Our study did not reveal any significant differences in
the subjective and objective evaluation between cromolyn
2% ophthalmic solution without preservative and that with
0.01% BAK in the 1-month period. This indicates that
for normal frequency and short-term use, cromolyn 2%
ophthalmic solution with 0.01% BAK is safe for most patients
with allergic conjunctivitis and would not cause significant
corneal erosion or other toxicity. Since the toxicity of BAK is
well documented, the lack of significant differences in
subjective and objective evaluation between the solution
with BAK and that without BAK may be due to the relatively
short duration of our trial. In our study, the case number
was relatively small and the range of evaluated score was
also narrow. It is probable not easy to detect the difference
between two groups. The short-term use of cromolyn 2%
ophthalmic solution with 0.01% BAK for 4 weeks may not be
long enough to present the toxicity of BAK. Therefore, in
acute or seasonal allergic conjunctivitis, there is no
significant benefit in choosing the more costly preservative-
free cromolyn over preservative-containing cromolyn if it is
used for less than 1 month. However, corneal erosion
significantly decreased in the group without preservative
but not in the group with 0.01% BAK after the 4-week
treatment. This may suggest that preservative-free eye
drops could be more beneficial to treat perennial or severe
allergic conjunctivitis, which requires long-term topical
cromolyn treatment or multiple drug combinations, and
they may possibly reduce BAK-induced ocular damages in
more vulnerable conditions such as in dry eyes, in limbal
insufficiency, or under long-term antiglaucoma medication.
Our study provides practical information for the clinicians
in the treatment of allergic conjunctivitis with cromolyn
2% ophthalmic solution. Since the treatment of allergic
conjunctivitis needs longer period, a further study with
longer time and larger cases may help to evaluate the
adverse effect of preservatives.
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